FDA Rejects Merck's Multiple Sclerosis Drug

by VR Sreeraman on  March 2, 2011 at 7:39 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

US Food and Drug Administration (FDA) has refused to approve Merck KGaA's oral pill Cladribine for multiple sclerosis treatment.
 FDA Rejects Merck's Multiple Sclerosis Drug
FDA Rejects Merck's Multiple Sclerosis Drug

The FDA declined to approve the drug "in its present form" and asked Merck to "provide an improved understanding of the safety risks and the overall benefit-risk profile," either through additional analyses or studies.

Merck said it would ask the US regulator to clarify the next steps and will try to address its questions.

The German pharmaceutical group has already been rebuffed by European regulators and has only received authorisation to sell Cladribine in Australia and Russia.

Shares in the company were down 0.65 percent to 64.58 euros in early trade on the Frankfurt stock exchange where the DAX index was off 0.91 percent overall.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Chemotherapy Chemotherapy Drugs Signature Drug Toxicity Infectious Mononucleosis Multiple Sclerosis Treatment and Modify Optic Neuritis Autoimmune Disorders Health Risks of Eating Pork 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive